Zoetis Inc. $ZTS Shares Purchased by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 27.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,326 shares of the company’s stock after acquiring an additional 41,175 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Zoetis were worth $13,605,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its position in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC lifted its holdings in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the last quarter. Finally, Glenview Trust co lifted its stake in shares of Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after buying an additional 506 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. BNP Paribas Exane reduced their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Finally, UBS Group decreased their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $107.43.

Zoetis Trading Down 0.5%

Shares of ZTS opened at $76.99 on Tuesday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market capitalization of $31.81 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The stock’s fifty day simple moving average is $75.59 and its 200 day simple moving average is $95.04. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the firm posted $1.76 earnings per share. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.